DVA
59
-3
AVY
46
2
XYL
7
-17
FITB
36
-4
KHC
49
-3
KMX
40
-2
FOXA
38
-4
AEE
45
-13
VRSN
40
-3
GS
33
-6
AZO
52
6
SHW
33
-10
IBM
54
-4
VIX
57
-6
AA
16
-10
EQR
31
-2
AON
63
-2
MPC
57
-3
CMS
55
-3
PX
40
-2
DVA
59
-3
AVY
46
2
XYL
7
-17
FITB
36
-4
KHC
49
-3
KMX
40
-2
FOXA
38
-4
AEE
45
-13
VRSN
40
-3
GS
33
-6
AZO
52
6
SHW
33
-10
IBM
54
-4
VIX
57
-6
AA
16
-10
EQR
31
-2
AON
63
-2
MPC
57
-3
CMS
55
-3
PX
40
-2
Financhill
Back

Keros Therapeutics Quote, Financials, Valuation and Earnings

Unexpected gains from AI stocks

Click here to see the proof for yourself.
Sell
28

KROS
Keros Therapeutics

Last Price:
32.89
Seasonality Move:
57.17%

7 Day Trial

ALL ACCESS PASS

$ 7

[Free Copy] Hedge Fund Black Book

Send Me My Free Copy!

Keros Therapeutics Price Quote

$32.89
+0.04 (+-0.36%)
(Updated: September 23, 2023 at 5:38 AM ET)

Keros Therapeutics Key Stats

Sell
28
Keros Therapeutics (KROS) is a Sell
Day range:
$32.32 - $33.93
52-week range:
$32.32 - $59.96
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
2.99%
Volume:
104K
Avg. volume:
193.6K
1-year change:
-6.36%
Market cap:
$974.4M
Revenue:
$0
EPS:
$-4.54

How Much Does Keros Therapeutics Make?

Data Unavailable

Is Keros Therapeutics Growing As A Company?

Data Unavailable

Keros Therapeutics Stock Price Performance

What Is Keros Therapeutics 52-Week High & Low?

Keros Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Keros Therapeutics?

Is Keros Therapeutics Cash Flow Positive?

  • What Is KROS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$111.1M
  • What Is Keros Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $219.4M
  • What Is Keros Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$1.9M

Keros Therapeutics Return On Invested Capital

Data Unavailable

Keros Therapeutics Earnings Date & Stock Price

Keros Therapeutics Competitors

  • Who Are Keros Therapeutics's Competitors?
    Below is a list of companies who compete with Keros Therapeutics or are related in some way:
    • Aldeyra Therapeutics Inc (ALDX)
    • Axsome Therapeutics Inc (AXSM)
    • Selecta Biosciences Inc (SELB)
    • Syndax Pharmaceuticals Inc (SNDX)
    • Sarepta Therapeutics Inc (SRPT)

Keros Therapeutics Dividend Yield

Data Unavailable

Keros Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 5.69%
Revenue: 0% -100%

Analyst Recommendations

Buy Recommendations: 7
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 90.25
Upside from Last Price: 174.73%

Major Shareholders

  • How many KROS shares are owned by institutional investors?
    34.2M KROS shares are owned by institutional investors
  • How many KROS shares are owned by insiders?
    372.2K KROS shares are owned by insiders